Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics. Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. The text is supplemented with 43 tables, 27 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 217 of these are profiled in the report with 471 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2009 and are projected to years 2014 and 2019. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders
TABLE OF CONTENTS0.Executive Summary15
1.Basics of Proteomics17
Nucleic acids, genes and proteins18
Decoding of mRNA by the ribosome20
Copyright©2010 PR Newswire.
All rights reserved